China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA) for its DTcP vaccine for infants and young children (under 2 years old), which was accepted for review by the National Medical Products Administration (NMPA) in December of last year, is now under priority review.
The DTcP vaccine, a component pertussis vaccine, ensures quality consistency between batches, resulting in more stable quality. Currently, there is no similar home-grown product on the market in China.
According to the Phase III clinical study, the primary immunization of this vaccine starts at 2 months of age and requires a total of 3 doses, with an interval of 1 or 2 months between each dose. The booster immunization is administered between 18 and 24 months of age, with each person receiving 1 dose.-Fineline Info & Tech
